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In most low- and middle-income countries (LMICs), bovine tuberculosis (bTB) remains
endemic due to the absence of control programs. This is because successful bTB
control and eradication programs have relied on test-and-slaughter strategies that
are socioeconomically unfeasible in LMICs. While Bacillus Calmette–Guérin (BCG)
vaccine-induced protection for cattle has long been documented in experimental and
field trials, its use in control programs has been precluded by the inability to differentiate
BCG-vaccinated from naturally infected animals using the OIE-prescribed purified protein
derivative (PPD)-based tuberculin skin tests. In the current study, the diagnostic specificity
and capability for differentiating infected from vaccinated animals (DIVA) of a novel defined
antigen skin test (DST) in BCG-vaccinated (Bos taurus ssp. taurus x B. t. ssp. indicus)
calves were compared with the performance of traditional PPD-tuberculin in both the skin
test and in vitro interferon-gamma release assay (IGRA). The IFN-γ production fromwhole
blood cells stimulated with both PPDs increased significantly from the 0 week baseline
levels, while DST induced no measurable IFN-γ production in BCG-vaccinated calves.
None of the 15 BCG-vaccinated calves were reactive with the DST skin test (100%
specificity; one-tailed lower 95% CI: 82). In contrast, 10 of 15 BCG-vaccinated calves
were classified as reactors with the PPD-based single intradermal test (SIT) (specificity in
vaccinated animals = 33%; 95% CI: 12, 62). Taken together, the results provide strong
evidence that the DST is highly specific and enables DIVA capability in both skin and
IGRA assay format, thereby enabling the implementation of BCG vaccine-based bTB
control, particularly in settings where test and slaughter remain unfeasible.
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INTRODUCTION
Bovine tuberculosis (bTB) is a chronic, granulomatous,
inflammatory disease that is predominantly caused by members
of the Mycobacterium tuberculosis complex (MTBC) in cattle.
The disease poses a significant threat to public health and
limits livestock productivity, resulting in an estimated economic
burden of $3 billion globally, annually (1). While bTB is well-
controlled in most high-income countries, it remains endemic
in low- and middle-income countries (LMICs) where national
control programs have not yet been implemented due to socio-
economic reasons (2–4). Further, the predicted intensification
of dairy and cattle farming will likely increase the associated
zoonotic risks, and the economic burden of the disease in the
coming years (5–7). Thus, there is a well-recognized urgent need
for alternate intervention programs such as vaccination to be
implemented in these geographies.
Bacillus Calmette–Guérin (BCG) is a live attenuated strain
of M. bovis that was initially isolated from the udder of
a tuberculous cow (8, 9). This M. bovis strain was serially
passaged for a period of 13 years (1908–1921) at the Pasteur
Institute and since has been used as a vaccine against TB
in humans. First evaluation of BCG against bTB in cattle
occurred 10 years prior, in 1912, and following promising
initial reports, the vaccine has been extensively evaluated in
both experimental and field trials. Encouragingly, numerous
reports have demonstrated BCG-induced protection in field
trials conducted in many different countries and settings (10).
However, despite this promise, BCG has previously not been
considered for widespread use as a livestock vaccine against bTB,
primarily due to its cross-reactivity with the OIE-recommended
purified protein derivatives (PPDs)-tuberculin based skin tests,
resulting in an inability to differentiate naturally M. tuberculosis
complex infected from BCG-vaccinated animals.
Currently, diagnosis of bTB in cattle is primarily based on the
detection of T cell-mediated immune response. This is routinely
performed using two diagnostic tests. The single intradermal
test (SIT) is the international standard and is based on the
use of PPD bovine (PPD-B)-tuberculin that represents culture
media sterile filtrates containing a large number of antigens
from a defined M. bovis strain, including those antigens that are
broadly cross-reactive with the BCG vaccine (11). Upon injection
in an infected animal, this elicits delayed-type hypersensitivity
(DTH) reactions with an animal considered reactor if there
is ≥4mm increase in skin thickness at 72 h post-injection. In
regions where exposure to environmental mycobacteria is an
important confounding factor in the diagnosis of bTB, the
comparative cervical tuberculin test (CCT) involving injection
of both bovine and avian PPDs (extracts from a M. avium
subsp. avium strain) is used to improve specificity, although
this is known to compromise sensitivity (12). Also, an IFN-γ
release assay (IGRA) is available as an ancillary test for improved
detection of bTB-infected animals and is based on the release
of IFN-γ by sensitized lymphocytes when re-exposed to MTBC
antigens in vitro (13).
Efforts in recent years have been focused on developing
BCG-compatible diagnostic tests with the ability to differentiate
infected from vaccinated animals (DIVA). Genomic and
transcriptomic analyses have identified ESAT-6, CFP10, and
Rv3615c as promising antigens for differential diagnosis of bTB
(14, 15). Recently, a novel defined antigen skin test (DST)
consisting of peptides representing these three antigens has
shown particular promise as a specific and sensitive test for
the detection of bTB-infected animals in both experimental
and field settings (16). While the specificity of this assay as a
skin test in naïve bTB-free control animals was also previously
determined, the specificity in BCG-vaccinated animals in field
settings is unknown. In the context of a BCG-based national
control program, the specificity of DST in correctly identifying
disease-free vaccinates as uninfected is crucial.
Hence, the current investigation was designed to assess the
utility of DST as a DIVA skin test in the face of BCG vaccination.
The results show that DST possesses high specificity both as a skin
test reagent and in in vitro assays in the face of BCG vaccination,
suggesting that application of DST provides an opportunity to
consider BCG vaccine-based bTB control programs in endemic
settings, especially where test and slaughter are unfeasible.
MATERIALS AND METHODS
Antigens and Peptides
Bovine tuberculin (PPD-B) and avian tuberculin (PPD-A) were
purchased from Prionics, Thermo Fisher, Schlieren, Switzerland.
The defined antigen skin test (DST) is a peptide-based cocktail
representing three antigens fromM. bovis viz, ESAT-6 (Mb3905,
equivalent to Rv3875 in M. tuberculosis with 100% identity),
CFP-10 (Mb3904, equivalent to Rv3874 in M. tuberculosis with
100% identity), and Rv3615c (equivalent to Mb3645c in M.
bovis with 100% identity). A total of 13 peptides representing
these three antigens were commercially synthesized at >98%
purity by GenScript USA, Inc. and USV Private Limited, India
(Supplementary Table 1 for peptide sequences). The in vivo
safety of DST was confirmed in B. taurus ssp. indicus under Good
Laboratory Practice (GLP) conditions in India with repeat and
overdosing experiments (unpublished).
Animals
The trial was conducted in India under field (normal animal
husbandry) conditions. In order to assess the skin test
performance of DST, 3- to 6-month-old crossbred calves (B.
taurus ssp. taurus X B. taurus ssp. indicus) were recruited from
bTB-free farms near Chennai, India. The population of crossbred
cattle in India increased by 26.9% in 2019 as compared to the
previous census (17). They are preferred in intensive farming
due to their ability to produce high milk yields. Following
recruitment, calves were housed in facilities at the Tamil Nadu
Veterinary and Animal Sciences University (TANUVAS), and
screened for helminths and dewormed during the acclimatization
period of 2 weeks. During the trial period, calves were fed with
milk initially and then with concentrate feed (a balanced mix
of grains, brans, minerals, and vitamins prepared by the Central
Feed Technology Unit at TANUVAS, and fed as a supplement
to grasses and silage), green fodder, and water ad libitum. All
cattle experiments were approved by the Institutional Animal
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FIGURE 1 | Timeline chart. Following arrival of calves on site, they were acclimatized for a period of 2 weeks. Vaccination of calves at week 0 denotes start of trial.
Blood was collected for Interferon-gamma release assay (IGRA) just prior to injection of BCG, and at weeks 4, 6, and 16 post-vaccination. Skin tests were conducted
at weeks 6 and 16.
Ethics Committee (IAEC) at TANUVAS and Committee for the
Purpose of Control and Supervision of Experimental Animals
(CPCSEA; F. No. 25/31/2017-CPCSEA). The trial timeline is
shown in Figure 1.
BCG Immunization
BCG Danish 1331 is among the most widely used TB vaccine
strain for humans and was also used in the current trial.
Freeze-dried preparations of BCG Danish strain were obtained
from Green Signal Bio Pharma Pvt. Ltd., India. These were
reconstituted as per-manufacturer instructions in 0.9% NaCl and
plated in duplicates on modified 7H11 agar plates in order to
determine the CFU of BCG (18). The plates were taped with
parafilm and incubated in sealed bags for 28 days at 37C before
counting the number of colonies on each plate. Calves were
randomly assigned to two groups of 15 each. The vaccinates were
subcutaneously administered a single dose (1–4 × 106 CFU) of
BCG Danish delivered in 0.5ml, at ∼3 to 6 months of age. This
dose was decided based on previous studies that have shown
relatively low doses of 104-106 CFU administered subcutaneously
to be efficacious in inducing protective immunity (1).
Intradermal Skin Test Procedures
PPD-tuberculins (PPD-B at 30,000 IU/ml and PPD-A at 25,000
IU/ml) were injected in a 0.1-ml volume as recommended by
the manufacturer and the OIE. The DST injection is composed
of 10 µg of each of the 13 peptides (0.1-ml final volume). The
dose was based on prior dose titration experiments performed in
cross-bred calves (B. taurus X B. taurus ssp. indicus) (19). The
same operator measured skin thickness before injection and at
72 h post injection, and readings were recorded in millimeters as
per OIE-prescribed guidelines (20).
Interferon Gamma Enzyme-Linked
Immunosorbent Assay (IFN-γ ELISA)
Bovine tuberculin (PPD-B) and avian tuberculin (PPD-A)
antigens were purchased from Thermo Fisher Scientific. The
BOVIGAMTM kit was used for the IFN-γ ELISA. The tuberculin
antigens (purchased from Thermo Fisher), PPD-B and PPD-
A, were used for in vitro stimulation of whole blood at a final
concentration of 300 and 250 IU/ml, respectively, as per the
kit instructions (antigens provided with the BOVIGAMTM kit
were not used in the assays). The DST was used at 10µg/ml
in in vitro assays. Blood was collected for IGRA just prior to
BCG vaccination at week 0, and just prior to skin test at weeks
4, 6, and 16. Whole blood was stimulated overnight (37C, 5%
CO2) with antigens (PPDs and DST) in vitro. BOVIGAM
TM
enzyme-linked immunosorbent assay-based kits (Thermo Fisher
Scientific, USA) were used to determine IFN-γ concentrations in
whole blood culture supernatants. Results for antigen-stimulated
cultures were expressed as background-corrected optical density
at 450 nm (i.e.,1OD450).
Statistical Analyses
Per the OIE guidelines for validation of diagnostic assays, this
sample size of 15 animals per group gives 95% power to
estimate a target specificity at least as good as CCT of ≥99.97%
(with 5% precision) (20). Confidence intervals (CIs) for the
specificity estimates in vaccinated animals for DST and PPDwere
calculated using the Clopper-Pearson method. For DST, with
technical specificity of 100% (no false positives within sample),
we calculated a one-sided CI (lower 95% CI: 82). Standard two-
sided CIs were calculated for PPD using the same method with
a point estimate of 33% (95% CI: 12, 62). All statistical analyses
were performed using Prism 8 (GraphPad Software, La Jolla,
CA). The Wilcoxon matched-pairs signed rank test (pairwise
difference, single-tailed and P = 0.05) was used for comparing
delta IFN-γ OD response between pre- and post-vaccination
time points. The IGRAs were performed at four time points
during the duration of the trial, the area under the curves (21)
were determined and the statistical difference was compared
using the Friedman (non-parametric) test. For skin test, statistical
difference between responses induced by the various antigens was
determined using the Friedman (non-parametric) test.
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RESULTS
DST Elicits Highly Specific IFN-γ Response
in BCG Vaccinated Calves as Measured
in vitro
To determine the diagnostic performance of DST in in vitro
assays, measurement of antigen-induced IFN-γ responses was
TABLE 1 | Summary of means of the IFN-γ responses stimulated by PPD-A,
PPD-B, and DST across all time points studied, in all calves tested.
Group Antigen Week
0 4 6 16
BCG PPD-B 0.21 (0.05) 0.45 (0.12) 0.65 (0.24) 0.37 (0.07)
PPD-A 0.22 (0.07) 0.44 (0.16) 0.63 (0.24) 0.38 (0.08)
DST 0 (0) 0 (0) 0 (0) 0 (0)
Control PPD-B 0.19 (0.03) 0.10 (0.04) 0.15 (0.05) 0.19 (0.04)
PPD-A 0.19 (0.03) 0.12 (0.05) 0.20 (0.08) 0.22 (0.04)
DST 0.01 (0.01) 0 (0) 0 (0) 0.01 (0.01)
The standard error of the mean is shown in parenthesis. Calves were vaccinated with
BCG at week 0. Blood was collected for IGRA just prior to injection of BCG, and at weeks
4, 6, and 16 post-vaccination. Skin test using PPDs and DST was conducted at weeks 6
and 16.
performed using whole blood collected at weeks 0, 4, 6, and
16 post-vaccination from all BCG vaccinates and controls.
Responses to avian and bovine PPD (PPD-A and PPD-B)
were measured to determine vaccine-induced IFN-γ response
Supplementary Table 1). At week 0, we detected low PPD-B
and PPD-A responses in most animals in both groups most
likely caused by cross-reaction with antigens from environmental
mycobacteria, although 3/30 would be classified as IGRA-positive
based on a PPD-B minus PPD-A > 0.1 OD value interpretation
of the test (Supplementary Table 1). Given that the specificity
of using tuberculin as stimulating antigen in IGRA is expected
to be around 95%, this is not an unexpected test outcome,
also given the fact that most animals at this time point were
younger than 6 months, the minimum age cut-off for IGRA to
avoid increased false-positive rates due to natural killer (NK)
cell activity (22). The IFN-γ production from whole blood cells
stimulated with both PPD-A and B increased significantly from
the 0 week baseline levels in BCG-vaccinated calves at each
of weeks 4, 6, and 16 (Table 1 and Figure 1). In contrast, no
such increase from baseline levels was noted in the unvaccinated
groups. While the observed group mean of IFN-γ responses to
PPD-A and B appeared to peak at week 6 (at 0.63 ± 0.24 and
0.65 ± 0.24, respectively), there were no statistically significant
FIGURE 2 | IFN-γ responses following BCG vaccination. Responses of BCG vaccinates (closed circle, n = 15) and controls (open circle, n = 15) to (A) PPD-B, (B)
PPD-A, and (C) DST. The background-corrected (delta) optical density (OD) values are plotted. Time is shown as weeks post-vaccination in the x-axis. Calves were
vaccinated with BCG at week 0. Blood was collected for IGRA just prior to injection of BCG, and at weeks 4, 6, and 16 post-vaccination. Skin test using PPDs and
DST was conducted at weeks 6 and 16. The pairwise difference between pre- and post-vaccination time points was determined using the Wilcoxon matched pairs
signed rank test (**P < 0.01; *P < 0.05). The dotted red line represents the IGRA cutoff of 0.1. (D) The bottom right panel provides the area under the curves (21),
where the horizontal line provides the median, and the statistical difference between the responses was determined using Friedman (non-parametric) test (****P <
0.0001).
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FIGURE 3 | Skin test responses induced by DST, PPD-B, and PPD-A were measured 72 h post-injection in calves vaccinated with BCG (n = 15) and naïve controls
(n = 15). Results are expressed as the difference in skin thickness (in millimeters) between pre- and post-skin test readings, with the horizontal line providing the
median [±95% confidence interval (CI)]. The statistical difference between the responses was determined using Friedman test (***P < 0.001). The dotted horizontal
lines at 2 and 4mm are the cutoffs used for DST, and PPD-B and PPD (B-A), respectively. The two control animals that are SIT positive are the same two that
show > 4mm PPD-A responses.
differences among any of the post-vaccination time points (4,
6, or 16 weeks) (Table 1 and Figure 2). The results were also
expressed as area under the curves to describe IGRA kinetic
responses (AUC; Figure 2D). Also of note, the results showed no
differences in the IFN-γ responses of whole blood from BCG-
vaccinated animals stimulated with either of the PPDs, suggesting
that BCG stimulates immune responses that are equally cross-
reactive to antigens contained in PPD-B and PPD-A (Table 1).
As expected, there were no statistical differences in the IFN-γ
stimulation responses among any of the unvaccinated control
calves to either of the PPDs at any time point (Table 1 and
Figure 2).
In stark contrast with the results of the PPDs, whole blood
stimulated with DST did not result in any appreciable IFN-
γ responses in either BCG vaccinated or unvaccinated control
calves at any of the observed time points, suggesting that the
DST is highly specific and exhibits no cross-reactivity in BCG
vaccinated calves (Table 1 and Figure 2).
DST Provides DIVA Capability in BCG
Vaccinated Calves
We next tested specificity of DST in skin tests in BCG-vaccinated
calves. Skin test responses to DST, PPD-A, and PPD-B were
recorded 6 weeks post-BCG vaccination, the time point with
the highest cell-mediated responses (Figure 2). The DST cocktail
induced minimal, if any, increase in skin thickness in both BCG
vaccinates and control calves 72 h post-injection (Figure 3). In
contrast, PPD-B induced a DTH response (of ≥4mm) in 10/15
(0.67; 95% CI: 0.42, 0.85) of BCG vaccinates and 2/15 (0.13; 95%
CI: 0.03, 039) unvaccinated controls that would be considered
as reactors per the traditional single intradermal test (Figure 3).
However, due to the equally high skin responses to PPD-A
observed in BCG vaccinated calves, none of the vaccinated
animals were classified as reactors under standard interpretation
conditions of the comparative cervical intradermal test (PPD-
B minus PPD-A > 4mm) (Figure 3). Of note, the animals in
the unvaccinated control group that exhibited ≥ 4mm PPD-B
stimulated skin induration responses also had a high (≥4mm)
PPD-A response (Figure 3).
DISCUSSION
BCG is the most widely used of all vaccines today (and
the only vaccine available against human TB). While BCG is
licensed for use in wildlife (23), it is not licensed for use in
domestic livestock because vaccination results in sensitization to
the PPD-based skin and IGRA tests. Hence, the development
of a diagnostic test that overcomes these limitations of the
OIE-recommended tuberculin-based skin tests to differentiate
infected from vaccinated animals is considered an essential
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prerequisite for the implementation of BCG vaccination of
cattle, particularly in settings where traditional test and slaughter
remain unfeasible (24).
In the early 1900s, the parent of BCG M. bovis isolate was
made to undergo ∼230 serial passages that resulted in its loss
of virulence in various animal models and consideration for
use as a vaccine in both cattle and humans (9, 25). Subsequent
genomic analyses revealed that the primary attenuating mutation
was likely the loss of an approximately 9.5-kb locus [termed as
“Region of Difference 1” (RD1)] prior to the clinical use of BCG
in 1921. All modern BCG vaccine substrains lack RD1, and the
complementation of RD1 has been shown to result in a protein
expression profile that is similar to that of the virulent strain,
confirming that this region harbors some of the major antigenic
targets identified thus far, including ESAT-6 and CFP-10 (26).
RD1 also encodes the esx1 secretion system, therefore resulting in
loss of immunogenicity of proteins dependent on this secretion
system, e.g., Rv3615c, in BCG. Since these antigens are present
in the genome of M. bovis but absent or not immunogenic in
BCG, they represent promising candidates for the development
of a DIVA diagnostic test for bTB, as has been previously
shown (14, 19).
We recently developed a synthetic peptide-based DST
(representing ESAT-6, CFP-10 and Rv3615c) and demonstrated
its considerable sensitivity in reliably detectingM. bovis-infected
animals in skin tests and in in vitro assays, while also maintaining
high specificity in naïve controls (16). However, the specificity of
DST in BCG-vaccinated animals in skin tests, in bTB endemic
settings, was unknown. The results of the current investigation
considerably extend the prior observation of specificity of DST
in BCG-vaccinated cattle in IGRA by now establishing the
specificity of the DST as a skin test reagent in BCG-vaccinated
and vaccine naïve calves, which is essential if DST were to be used
as a DIVA diagnostic in field settings (16).
The IGRA results from these 3- to 6-month-old cross-bred
calves (Jersey X. Zebu) in India to PPD-A and PPD-B at the start
of the study (0th week, pre-vaccination) suggest pre-sensitization
from high levels of exposure to environmental mycobacteria and
pathogenic mycobacteria, including Mycobacterium avium ssp.
paratuberculosis in these geographies (27, 28). While in general,
due to non-specific IFN-γ production, minimum eligible age for
BOVIGAMTM assays is 6 months, the whole blood cells derived
from pre-BCG vaccinated calves remained unreactive to DST
(Table 1 and Figure 2) (29). Also, the equivalent PPD-B and
PPD-A skin responses observed in BCG-vaccinated calves in our
studies was noteworthy since PPD-B, which is derived from a
M. bovis strain, might be expected to share greater antigenic
similarity to BCG than a M. avium subsp. avium strain from
which PPD-A is derived (11). Contrary to this expectation, the
results of our studies suggest that while BCG likely stimulates a
broadly cross-reactive (non-specific) response to mycobacteria,
the specificity is driven by antigens, such as those that are
encoded by or dependent on the RD1 locus that is missing in
BCG. In this context, since the DST consists of antigens present
only in members of the M. tuberculosis complex and a few
other pathogenic mycobacteria (M. leprae and M. kansasii), it
would be expected to provide superior specificity over PPD-B
alone as observed in our current studies. It is also important to
note that given the cross-reactivity between PPD-B and PPD-
A, there are serious implications for the sensitivity of CCT in
settings such as in India where there is likely a high burden
of environmental mycobacteria. In such conditions of high
background environmental mycobacterial exposure that drives
PPD-A reactivity, CCT would result in a high proportion of
false-negative results whereas SIT, performed with PPD-B alone,
would result in a high proportion of false positives (12). Hence,
although the current study suggests that BCG-vaccinated calves
would be considered to be non-responders in the CCT assay, the
general utility of CCT in conditions such as those encountered
in India and other countries with high environmental burden
remains unclear.
Another interesting observation is that animal IDs 69 and 80
remained relatively unresponsive to BCG immunization based
on the trajectories of their immune responses as measured by
IGRA over time (Supplementary Table 1). While the reason
for this is unclear, it is crucial for future studies to identify
biomarkers to confirm vaccine-induced protection in order to
formulate evidence-based approaches to the development of a
bTB control program. Importantly, in contrast to PPDs, DST was
highly specific—revealing no cross-reactivity with environmental
mycobacteria in both whole blood IGRA and in the skin test.
The observation that DST specificities are not impaired under
field conditions in highly endemic settings is encouraging and
suggests that the DST may overcome the specificity limitations
of traditional PPD-based skin tests both in the face of both
BCG vaccination and due to sensitization with saprophytic
mycobacteria that also likely complicate interpretation and
clinical sensitivity of the CCT. Although the group sizes of
the current study are relatively low, these are crucial proof-
of-concept experiments that demonstrate the much-needed
DIVA capability of a diagnostic test in order to enable the
implementation of livestock vaccination programs in regions in
which bTB is endemic and remains uncontrolled, and where
test and slaughter remain unfeasible. We note that it is crucial
to evaluate the performance of DST in vaccinated animals that
subsequently become infected.
In summary, this study confirms that DST allows not
only discrimination between infected animals and those
environmentally sensitized but also its utility as a much-needed
DIVA test reagent in a challenging geographical context. Thereby,
the DST has the potential to overcome a major hurdle for
the implementation of BCG cattle vaccination programs as an
intervention strategy for disease control.
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